Vnitr Lek 2018, 64(12):1153-1155

"The higher the better" seems to be no longer true for HDL-cholesterol

Hana Rosolová
Centrum preventivní kardiologie II. interní kliniky LF UK a FN Plzeň

It is very well known from the old epidemiological population studies, that HDL-cholesterol (HDL-C) was in a negative association with coronary events risk. New studies have occurred during the last 10 years that the mentioned association has in fact the U-shaped curve, i.e. lower and higher levels of HDL-C then the optimal one are in an exponential increasing risk. The association of high HDL-C levels with cardiovascular risk is not explained clearly. There might be a hypothesis concerning a change of function of large HDL particles riched of cholesterol esters, which become to be cholesterol donors for the arteries.

Keywords: cardiovascular risk; HDL-cholesterol; HDL particles

Received: November 11, 2018; Accepted: November 15, 2018; Published: December 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosolová H. "The higher the better" seems to be no longer true for HDL-cholesterol. Vnitr Lek. 2018;64(12):1153-1155.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Multiple Risk Factor Intervention Trial Research Group: MRFIT: a National study of primary prevention of coronary heart disease. JAMA 1976; 235(8): 825-827. Go to original source...
    2. Allard-Ratick M, Fonarow G. HDL-cholesterol is associated with adverse cardiovascular outcomes. European Society of Cardiology meeting, Munich, Germany, Aug. 25, 2018. Dostupné z WWW: <https://content.zone-secure.net/escardio_congress_2018/#page=1>. Go to original source...
    3. Van der Steeg WA, Holme I, Boekholdt SM et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 2008; 51(6): 634-642. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.09.060>. Go to original source... Go to PubMed...
    4. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017; 38(32): 2478-2486. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx163>. Go to original source... Go to PubMed...
    5. Kastelein JJ, van Leuven SI, Burgess L et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med 2007; 356(16): 1620-1630. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071359>. Go to original source... Go to PubMed...
    6. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with orat high risk for coronary heart disease. N Engl J Med 2010; 363(25): 2406-2415. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1009744>. Go to original source... Go to PubMed...
    7. Bowman L, Hopewell JC, Chen F et al. [HPS3/TIMI55-REVEAL Collaborative Group]. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017; 377(13): 1217-1227. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1706444>. Go to original source... Go to PubMed...
    8. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 2002; 110(7): 899-904. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI16391>. Go to original source... Go to PubMed...
    9. Navab M, Anatharamaiah GM, Reddy ST et al. Mechanisms of disease: proatherogenic HDL - anevolving field. Nat Clin Pract Endocrinol Metab 2006; 2(9): 504-511. Dostupné z DOI: <http://dx.doi.org/10.1038/ncpendmet0245>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.